iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Average PT from Brokerages

iRadimed Corporation (NASDAQ:IRMD) has been given an average rating of “Buy” by the five research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $120.00.

Several equities analysts have recently issued reports on the stock. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. This represents a 0.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 47,500 shares of company stock worth $4,279,303. Insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after buying an additional 5,475 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after buying an additional 205,783 shares during the period. Dimensional Fund Advisors LP increased its holdings in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after buying an additional 9,017 shares during the period. Goldman Sachs Group Inc. increased its holdings in iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after buying an additional 55,426 shares during the period. Finally, State Street Corp increased its holdings in iRadimed by 3.1% in the 4th quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after buying an additional 5,713 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Stock Performance

IRMD stock opened at $93.96 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 51.34 and a beta of 0.91. The firm has a 50-day simple moving average of $90.42 and a two-hundred day simple moving average of $95.86. iRadimed has a one year low of $55.11 and a one year high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts predict that iRadimed will post 1.52 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s payout ratio is currently 43.72%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.